← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Antidote Therapeutics, Inc.
Sykesville, MD
$21,780,207
Total funding
3
Grants
Funding over time
peak $5.2M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,780,207 · 3
By mechanism
U01$13,125,765 · 1
R01$8,453,608 · 1
R43$200,834 · 1
Investigators at Antidote Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
IND-enabling Studies in Support of First in Human Safety Studies of a Novel Anti-Nicotine Human Monoclonal Antibody$5,215,321
U01 · FY2024 · DA
IND-enabling Studies in Support of First in Human Safety Studies of a Novel Anti-Nicotine Human Monoclonal Antibody$4,026,705
U01 · FY2023 · DA
IND-enabling Studies in Support of First in Human Safety Studies of a Novel Anti-Nicotine Human Monoclonal Antibody$3,883,739
U01 · FY2025 · DA
Lead Optimization and Preclinical Development of Human Nicotine-Specific mAbs$2,960,853
R01 · FY2015 · DA
Lead Optimization and Preclinical Development of Human Nicotine-Specific mAbs$2,939,717
R01 · FY2016 · DA
Lead Optimization and Preclinical Development of Human Nicotine-Specific mAbs$2,553,038
R01 · FY2014 · DA
Protein Engineering of a Biologic Drug Candidate$200,834
R43 · FY2017 · DA